CatalystWireBeta

UK small-cap RNS · 15 Jan 2026

Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.

Sort: Newest · Largest companies
  1. 07:00
    Full Year trading update and notice of results
    FY25 trading performance in line with market expectations, with improving operating margins and a stabilised order book
    +4.7% on the day
  2. 07:00
    Transaction in Own Shares Routine
  3. 07:00
    Transaction in Own Shares Routine
  4. 07:00
    Q3 leasing update
    Great Portland Estates plc (GPE) publishes a leasing update for the quarter to 31 December 2025.
    +3.5% on the day
  5. 07:00
    Half-year Results Results
    H1 revenue up 13% to £11.6m with EBITDA of £0.9m and the loss after tax cut to £0.1m, as the chairman's October 'strong results' pre-signal said. Both divisions improved and H2 is guided stronger.
    Sale process / strategic review ahead of expectationsoutlook positivefirst in 11 months +2.2% on the day
    Moved: Obtain Workday certification by mid-FY26 and build pipeline: pending → on_track – Workday integration is stated to be in place, but certification is not mentioned, so it is not confirmed. · Complete development of next-generation access control product in the next finan: pending → delayed – The Janus C4 Ultra access control product is held back by software partner delays; investment was refocused on HCM and Access Control strategy is under review. · Safetell strategic review: Review advancing; costs cut, sales up → review ongoing; salary costs cut c.15%
  6. 07:00
    Rule 19.6(b) update and Rule 19.6(c) confirmation
    Rule 19.6(b) update and Rule 19.6(c) confirmation with respect to the stated post-offer intentions made with regard to Condor Gold plc
    −1.3% on the day
  7. 07:00
    Trading Statement Trading update
    Ashmore Group plc (Ashmore, the Group), the specialist Emerging Markets asset manager, announces the following update to its assets under management (AuM) in respect of the quarter ending 31 December 2025.
    +23.5% on the day
  8. 07:00
    Transaction in Own Shares Routine
  9. 07:00
    Transaction in Own Shares Routine
  10. 07:00
    Transaction in Own Shares Routine
  11. 07:00
    Half-year Results Results
    This is only the notice that the interim report is now posted and on the website. The figures were already released on 10 December 2025, so it adds no new financial information.
    −1.6% on the day
  12. 07:00
    Transaction in Own Shares Routine
  13. 07:00
    Transaction in Own Shares Routine
  14. 07:00
    Annual Report Results
    FY25 was in line with expectations, and the turnaround is showing: gross margin rose from 28.0% to 32.9%, underlying EBITDA from £5k to £811k, and the underlying pre-tax loss narrowed to £40k.
    Turnaround plan with targets £15.8m · 170% of mcapin lineoutlook mixedfirst in 8 months −5.1% on the day
    Moved: Develop a 3-5 year strategy by end of FY24: pending → delivered – The five-year strategic plan was launched in 2024 and is now being executed. · Meaningful gross margin improvement within 12-18 months: pending → delivered – Gross margin rose 4.9 points to 32.9%, with improvements in both business units. · Achieve 10% organic revenue growth and 15% net margin by 2028: pending → on_track – Management says FY25 positions the Group for further progress towards the 2028 targets. FY25 revenue growth was only 2.1%, against a 10% target.
  15. 07:00
    Transaction in Own Shares Routine
  16. 07:00
    Transaction in Own Shares Routine
  17. 07:00
    Full Year 2025 Trading Update Trading update
    FY2025 revenue of about £228.5m (2024: £177.5m) and EBITDA of £49.5-50.0m (2024: £40.2m) meet market expectations, with surgical growth and a woundcare recovery offsetting Peters Surgical B2B destocking.
    £228.5m · 37% of mcapin lineoutlook positivefirst in 6 months +0.9% on the day
    Moved: new: Peters Surgical and Syntacoll integration – Integration on track; commercial synergies contributing · new: US market expansion – Plans for further US penetration well advanced
  18. 07:00
    Transaction in Own Shares Routine
  19. 07:00
    Transaction in Own Shares Routine
  20. 07:00
    Transaction in Own Shares and Total Voting Rights Routine
  21. 07:00
    Transaction in Own Shares Routine
  22. 07:00
    Transaction in Own Shares Routine
  23. 07:00
    Transaction in Own Shares Routine
  24. 07:00
    Transaction in Own Shares Routine
  25. 07:00
    Transaction in Own Shares Routine
  26. 07:00
    Transaction in Own Shares Routine
  27. 07:00
    Transaction in Own Shares Routine
  28. 07:00
    Transaction in Own Shares Routine
  29. 07:00
    Transaction in Own Shares Routine
  30. 07:00
    Trading Update Trading update
    Confirms full-year adjusted operating profit in line with consensus (£70.2m-£73.0m) after a weak H1. Q3 I&A orders are growing, so the H2 recovery looks on course.
    Segment turn £48.5m · 4% of mcapin lineoutlook positive +5.4% on the day
    Moved: NanoScience business sale: Agreed; awaiting regulatory approvals → Completed 2 January 2026 (closed) · Imaging & Analysis recovery: H1 actions taken; H2 recovery expected → Q3 orders +2.4%; Belfast savings delivering
  31. 07:00
    Transaction in Own Shares Routine
  32. 07:00
    Transaction in Own Shares Routine
  33. 07:00
    Transaction in Own Shares Routine
  34. 07:00
    Corporate Update
    Reports 2025 revenue up about 330% and gross margin up 150% on FY2024 (a period from incorporation on 23 Feb 2024), with active clients up over 225% and retention around 90%. The comparison base is a short first period.
    outlook positive +4.8% on the day
    Moved: new: Corporate client base expansion – Initial corporate orders secured; further talks ongoing
  35. 07:00
    Fourth Quarter Update
    • Funds under management and administration ("FUMA") increased 2.3% to £115.6 billion at 31 December 2025 (30 September 2025: £113.0 billion; 31 December 2024: £109.2 billion) comprising:
    +7.8% on the day
  36. 07:00
    Exercise of Warrants and Total Voting Rights
    Jangada Mines plc / EPIC: JAN.L / Market: AIM / Sector: Mining
    −6.5% on the day
  37. 07:00
    Transaction in Own Shares Routine
  38. 07:00
    Quarterly Conference Call Details
    Thursday, 22 January 2026 at 8:00pm (AEDT) 9:00am (GMT)
    +4.6% on the day
  39. 07:00
    Transaction in Own Shares Routine
  40. 07:00
    OSB Group OSB £1,615m
    OSB GROUP PLC - Transaction in Own Shares Routine
  41. 07:00
    Form 38.5(b) - Permanent TSB Group Holdings plc Routine
  42. 07:00
    Form 38.5(b) - Permanent TSB Group Holdings plc Routine
  43. 07:00
    Form 38.5(a) - Permanent TSB Group Holdings plc Routine
  44. 06:30
    Reports Q4-2025 Production, Record Annual Production, Production Guidance Achieved & Operational Highlights
    Serabi Gold plc (“Serabi” or the “Company”) (AIM:SRB, TSX:SBI, OTCQX:SRBIF), the Brazilian focused gold mining and development company, is pleased to announce the Company’s fourth quarter production results and operating highlights for FY2025 (all financial …
    in linefirst since Oct 2023 −0.3% on the day

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note